Author

G. Wirjanata

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:drug response / drug discovery· 2 Research Focus:host-pathogen & immune response· 1 Organism:human· 1 Organism:non-human primate· 1 Organism:plant (other)· 1 Assay:proteomics· 1

Frequent Co-Authors

Z. Bozdech· 2 shared A. El Sahili· 1 shared A. Partridge· 1 shared C. D. Suraweera· 1 shared C. Giannangelo· 1 shared D. J. Creek· 1 shared D. Olsen· 1 shared F. Achcar· 1 shared

Activity by Year

2021-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 17 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersMicrobiology

Z. Bozdech

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

On-target, dual aminopeptidase inhibition provides cross-species antimalarial activity.

R. C. Edgar, G. Siddiqui, T. R. Malcolm, S. Duffy, M. Chowdhury, J. Marfurt, G. Wirjanata, R. Noviyanti, K. Daware, M. Dans, C. D. Suraweera, N. A. Counihan, R. N. Price, S. Whittlin, V. M. Avery, , S. McGowan

This paper identifies MMV1557817 as a dual aminopeptidase inhibitor effective against multiple Plasmodium species and highlights its potential as a multi-target antimalarial drug.

bioRxiv · Oct 1, 2023Microbiology

Repeated Plasmodium vivax blood stage infection provides sterile protection against homologous challenge in non-human primates

N. Obaldia, J. L. da Silva Filho, M. Nunez, K. Glass, T. Oulton, F. Achcar, G. Wirjanata, M. Duraisingh, P. Felgner, K. Tetteh, Z. Bozdech, T. Otto, M. Marti

This study shows that repeated P. vivax infections in Aotus monkeys induce sterile immunity against homologous strain challenges but only partial protection against heterologous strains.

bioRxiv · Feb 13, 2023 · PreprintMicrobiology

Identification of an inhibitory pocket in falcilysin provides a new avenue for malaria drug development

G. Wirjanata, J. Lin, J. Dziekan, A. El Sahili, Z. Chung, S. Tjia, N. E. B. Zulkifli, J. Boentoro, R. Tham, S. J. Lai, K. Go, Y. Han, A. Partridge, D. Olsen, N. Prabhu, , Z. Bozdech

This study identifies falcilysin as a target of anti-malaria drugs and reveals a shared inhibitory pocket that could guide new drug development.

bioRxiv · Apr 8, 2021Microbiology